Clinical studies NIDDM

Dills DG, Schneider I, et. al. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996,28 426-429. 

Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract 1995 28(Suppl) S147-9. 

According to modern pathophysiological understanding of Type-II diabetes and the mechanism of sulphonylurea action, combined insulin-sulphonylurea therapy appears to be an interesting alternative for treating NIDDM patients with secondary failure to sulphonylureas. Several recent clinical trials confirmed favourable results (Stenman et al., 1988). Holman et al. (1987) studied the metabolic profiles of 24 Type-II diabetics who were treated... 

Acarbose is used in diabetes in addition to other therapeutic regimes in connection with diet. Its clinical usefulness was demonstrated (Hanefeld et al., 1991) but its extent is a matter of controversy. However, a diet is preferable in Type-II diabetes. There are some studies which show the usefulness of its combination with sulphonylureas. Considerable individual variation is noted in the response to acarbose (Reaven et al., 1990). The use of acarbose in patients with NIDDM not well controlled by sulphonylureas appears to have significant clinical benefit (Raptis et al., 1982). One study suggests that it is not an effective substitute for sulphonylureas in non-obese Type-II diabetes uncontrolled by diet alone (Buchanan et al., 1988). 

---